| Literature DB >> 29686719 |
Laura Gaman1, Dorin Dragos1,2, Adelina Vlad1, Georgiana Catalina Robu1, Mugurel Petrinel Radoi1,3, Laura Stroica1, Mihaela Badea4, Marilena Gilca1.
Abstract
Despite recent advances in understanding the complex pathogenesis of pancreatitis, the management of the disease remains suboptimal. The use of phytoceuticals (plant-derived pleiotropic multitarget molecules) represents a new research trend in pancreatology. The purpose of this review is to discuss the phytoceuticals with pancreatoprotective potential in acute pancreatitis and whose efficacy is based, at least in part, on their capacity to modulate the acinar cell death. The phytochemicals selected, belonging to such diverse classes as polyphenols, flavonoids, lignans, anthraquinones, sesquiterpene lactones, nitriles, and alkaloids, target the balance between apoptosis and necrosis. Activation of apoptosis via various mechanisms (e.g., inhibition of X-linked inhibitor of apoptosis proteins by embelin, upregulation of FasL gene expression by resveratrol) and/or inhibition of necrosis seem to represent the essential key for decreasing the severity of the disease. Apart from targeting the apoptosis/necrosis balance, the phytochemicals displayed other specific protective activities: inhibition of inflammasome (e.g., rutin), suppression of neutrophil infiltration (e.g., ligustrazine, resveratrol), and antioxidant activity. Even though many of the selected phytoceuticals represent a promising therapeutic alternative, there is a shortage of human evidence, and further studies are required to provide solid basis to justify their use in the treatment of pancreatitis.Entities:
Year: 2018 PMID: 29686719 PMCID: PMC5857302 DOI: 10.1155/2018/5264592
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Animal models of pancreatitis.
| Chemical inducer | Characteristics | Pancreatitis type | References |
|---|---|---|---|
| Bile salts | Mechanical temporary blockage of bile duct, detergent effect of the bile salts, and hemorrhagic necrosis | Severe AP | [ |
|
| |||
| Cerulein | Stimulation of pancreatic enzyme production, inhibition of zymogen granules exocytosis, NADPH oxidase activation, increased reactive oxygen species generation, NF- | Mild AP | [ |
|
| |||
| L-arginine | Increased production of amylase, lipase, and trypsinogen, markedly swollen mitochondria, and degenerative changes of intracellular organelles and nuclei | Severe necrotizing AP | [ |
|
| |||
| Alcohol +/− high fat diet | Stellate cell activation, fibrosis, and acinar cell mass shrinkage | Mild CP | [ |
|
| |||
| Dibutyltin dichloride | Edema (24 h), mononuclear cells infiltration (day 7), bile duct epithelium necrosis, upregulation of transforming growth factor- | AP | [ |
|
| |||
| CCK | Increased plasma amylase, lipase, trypsin-like immunoreactivity, pancreatic parenchymal swelling, and interlobular and subcapsular fluid accumulation | AP | [ |
AP: acute pancreatitis, CCK: cholecystokinin, and CP: chronic pancreatitis.
Figure 1Mechanisms underlying the balance between apoptosis and necrosis in acute pancreatitis (FasL: Fas ligand, FasR: Fas receptor, IAP: inhibitor of apoptosis proteins, DAMP: damage-associated molecular patterns, RIPK: receptor-interacting protein kinases, TLR: toll-like receptors, and TNFR: TNF receptor).
Phytoceuticals effects in acute pancreatitis (animal studies) and their proposed mechanism of action.
| Animals/cell type used | Dose, route of administration, | AP model | Findings | Ref. |
|---|---|---|---|---|
|
| ||||
|
| ||||
| Male Wistar rats | 50 mg/kg artemisinin | i.p. 20 | ↑ apoptosis, caspase-3, | [ |
|
| ||||
| Male SD rats | 0.70, 1.75 and 3.50 mg/kg artesunate | r.i.BPD 3.5% sodium taurocholate | ↑ survival rate | [ |
|
| ||||
|
| ||||
|
| ||||
| SD rats | 5%, i.v.b. 10 mg/100 g f.c.i.v.i. 10 mg/h/100 g | r.i.BPD 3.5% sodium taurocholate | ↓ renal pathological changes, mortality, renal Bcl-2 protein, serum NO, plasma endotoxin, serum BUN, IL-6, ET-1, TNF- | [ |
|
| ||||
| Male SD rats | 5%, i.v.b. 10 mg/100 g f.c.i.v.i. 10 mg/h/100 g | r.i.BPD 3.5% sodium taurocholate | ↓ TNF- | [ |
|
| ||||
| SD rats | 5%, i.v.b. 10 mg/100 g f.c.i.v.i. 10 mg/h/100 g | r.i.BPD 3.5% sodium taurocholate | ↓ mortality, endotoxin, TNF- | [ |
|
| ||||
| SD rats | 5%, i.v.b. 10 mg/100 g f.c.i.v.i. 10 mg/h/100 g | r.i.BPD 3.5% sodium taurocholate | ↓ mortality, pathological severity scores, plasma endotoxin, serum PLA2, ET-1, NO, P-selectin | [ |
|
| ||||
|
| ||||
|
| ||||
| Female CD-1 mice | i.v.b. 70 mg/kg | i.p. 50 | ↓ amylase, pancreatic edema, necrosis (12 h after pre-trt.) | [ |
|
| ||||
| Male Swiss mice | i.v.b. 70 mg/kg | i.p. 50 | ↑ apoptosis | [ |
|
| ||||
|
| ||||
|
| ||||
| Albino rats | i.p. 50 mg/kg/d × 6 d (pre-AP induction, post-AP induction or no-AP induction, resp.) | 250 mg/100 g L-arginine i.p., twice at an interval of 1 h | ↓ amylase, lipase, NAP78, protein carbonyls, TNF- | [ |
|
| ||||
| Male SD rats | i.p. 100 mg/kg | r.i.BPD 5% sodium taurocholate | ↓ ascites, amylase, TNF- | [ |
|
| ||||
| WA rats | i.g. 100 mg/kg (curcumin in alcohol) 20 d before AP induction and all through the study | r.i.BPD 3% sodium taurocholate | ↓ total histopathologic scores, trypsin activity, NF- | [ |
|
| ||||
| Kun Ming male mice | i.p. 50 mg/kg/d × 6 d | i.p. 50 | ↓ pancreas injury, amylase, ALT, AST, TNF- | [ |
|
| ||||
| Male SD rats | i.v. 35 mg/kg/h × 6 h | i.v. cerulein (5 | ↓ pancreas injury (histologic changes, amylase, trypsin, neutrophil infiltration) ↓ NF- | [ |
|
| ||||
| Male SD rats | i.p. 20 mg/kg | 2 h ischemia → 6 h reperfusion | ↓ amylase, HO | [ |
|
| ||||
|
| ||||
|
| ||||
| Male SD rats and male Swiss Webster CD-1 mice | s.c. 20 mg/kg × 5 d | i.p. 50 | ↓ pancreatic necrosis and ↑ apoptosis in mouse model, ↑ caspase-9, -3, -8 in mouse model | [ |
|
| ||||
|
| ||||
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg q6 h | r.i.BPD 5% sodium taurocholate | ↑ pancreatic blood flow | [ |
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg q6 h | r.i.BPD 5% sodium taurocholate | ↓ TXB2 | [ |
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg q6 h | r.i.BPD 5% sodium taurocholate | ↓ TXB2 | [ |
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg | r.i.BPD 5% sodium taurocholate | ↓ TNF- | [ |
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg | r.i.BPD 5% sodium taurocholate | ↓ TNF- | [ |
|
| ||||
| Male SD rats | orally 20/40/80 mg/kg × 28 days | r.i.BPD trinitrobenzene sulfonic acid | ↓ TGF- | [ |
|
| ||||
| SD rats | i.v. 2.5 mg/kg | r.i.BPD 3.5% sodium taurocholate | ↑ intestinal transit | [ |
|
| ||||
| SD rats | i.v. 2.5 mg/kg | r.i.BPD 3.5% sodium taurocholate | ↓ amylase, histological damage, edema, vacuolization, inflammation, necrosis, NF- | [ |
|
| ||||
| SD rats | i.v. 2.5 mg/kg | r.i.BPD 1.5% sodium deoxycholate | ↑ mCD14 & ICAM-3 expression in pMΦs | [ |
|
| ||||
| SD rats | i.v. 2.5 mg/kg | r.i.BPD 1.5% sodium ursodeoxycholate | ↓ amylase, lung edema, pathological changes, serum TNF- | [ |
|
| ||||
| SD rats | i.v. 2.5 mg/kg | r.i.BPD 3% sodium cholate | ↓ apoptosis of intestinal mucosa cells, translocation of bacteria and endotoxin | [ |
|
| ||||
| RPA AR42J cells | 10 and 20 | cerulein (10−7 M) + lipoplysaccharide (10 mg/l) | ↓ amylase | [ |
|
| ||||
|
| ||||
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg for EM, 20 mg/kg for BA | r.i.BPD 5% sodium taurocholate | ↓ amylase, TNF- | [ |
|
| ||||
| Male SD rats | i.v. 2.5 mg/kg/6 h for EM, 20 mg/kg/6 h for BA | r.i.BPD 5% sodium taurocholate | ↓ mortality, ascites, pancreatic pathological scores, amylase, TNF- | [ |
|
| ||||
|
| ||||
|
| ||||
| Male Wistar rats | EM (3.0 mg/100 g) by enteral tube q10 h × 6 times | r.i.BPD 5% sodium taurocholate | ↓ amylase, ALT, AST, MDA, hepatic & pancreatic MPO, TNF- | [ |
|
| ||||
|
| ||||
|
| ||||
| WA rats | 0.3 g/kg s.c. | cerulein 50 | ↓ amylase, inflammatory infiltrate, edema, ROS burden, NO | [ |
|
| ||||
| RPA AR42J cells | 53.7 | cerulein | ↑ cell viability, apoptosis index; ↓ necrosis, LDH released from the cells, ROS generation | [ |
|
| ||||
|
| ||||
|
| ||||
| RPA AR42J cells | 9.07 | cerulein | ↑ cell viability, apoptosis index; ↓ necrosis, LDH released from the cells | [ |
|
| ||||
|
| ||||
|
| ||||
| Adult SD rats | i.p. 150 mg/kg/day, 3 days | i.p. 100 | ↓ amylase, pancreatic MPO, TNF- | [ |
|
| ||||
| SD rats | NP | r.i.BPD 5% sodium taurocholate. | ↑ survival rate, 6-keto-PGF1 alpha | [ |
|
| ||||
|
| ||||
|
| ||||
| RPA AR42J cells | 1.49 | cerulein | ↑ cell viability, apoptosis index; ↓ necrosis, LDH released from the cells, ROS generation | [ |
|
| ||||
| BALB/c mice | i.v. magnolol immediately after the AP model was reproduced, then at 9, 12, 24 hours after modelling | i.p. cerulein hourly 7 times | ↓ amylase, pancreatic histopathologic score | [ |
|
| ||||
|
| ||||
|
| ||||
| RPA AR42J cells | 53.7 | cerulein | ↑ cell viability, apoptosis index | [ |
|
| ||||
|
| ||||
|
| ||||
| Swiss albino rats | 30 mg/kg/h, orally, thrice at 1 h intervals | cerulein |
| [ |
|
| ||||
|
| ||||
|
| ||||
| SD male rats | 30 mg/kg b.m. intraperitoneally | r.i.BPD 4% sodium taurocholate | ↓ NF- | [ |
|
| ||||
| Male Wistar rats | 10 mg/kg i.p. 30 min pre-trt. | s.c. 3 × 75 | ↓ amylase, lipase, total pancreatic histological damage, edema, acinar vacuolization | [ |
|
| ||||
| Male SD rats | 10 mg/kg, injected through penal vein 5 min post-trt. | r.i.BPD 4% sodium taurocholate | ↓ severity, NF- | [ |
|
| ||||
| Male SD rats | i.v. 20 mg/kg, 5 min post-trt. | r.i.BPD 4% sodium taurocholate | ↑ SOD | [ |
|
| ||||
| Male SD rats | i.p. 10 mg/kg | r.i.BPD 4% sodium taurocholate | ↑ Bcl-2 | [ |
|
| ||||
| Male SD rats | i.v. 20 mg/kg, 10 min after SAP induction | r.i.BPD 4% sodium taurocholate | ↓ amylase, MDA, neutrophil infiltration in pancreas | [ |
|
| ||||
|
| ||||
|
| ||||
| SD rats | p.o. 10, 20, or 50 mg/kg/h | i.p. | ↓ amylase, lung injury, pulmonary levels of TNF- | [ |
|
| ||||
| SD rats | NP | i.p. repetitive administration, cerulein 50 | ↓ amylase, lung injury, NF- | [ |
|
| ||||
|
| ||||
|
| ||||
| RPA AR42J cells | 479, 119.8, and 29.9 | cerulein | ↑ apoptotic-to-necrotic cell ratio, p53, cytochrome C, caspase-3, Bax/Bcl-2 ratio (dose dependent) | [ |
|
| ||||
| male SD rats | 10 mg/kg rhein (conjugated with HPDM) | r.i.BPD 3% or 5% sodium taurocholate | ↓ amylase, MPO, histological damage in pancreas (inflammatory infiltrate, acinar cell vacuolization & necrosis), ↓ IL-6, TNF- | [ |
|
| ||||
| RPA AR42J cells | 479 | cerulein | ↑ cell viability, apoptosis index; ↓ necrosis, LDH released from the cells, ROS generation | [ |
|
| ||||
|
| ||||
|
| ||||
| Swiss mice | p.o. 37.5, 75, or 150 mg/kg, after 24, 36, 48, and 60 h of AP induction | i.p. 8% L-arginine hydrochloride 4 g/kg twice | ↓ pain, amylase, lipase, CRP, IL-6, pancreatic MPO, edema index, necrosis, MDA, 3-nitrotyrosine | [ |
|
| ||||
| Male albino Wistar rats | p.o. 100 mg/kg/day from the third week | p.o. ethanol (36% of total calories) 5 weeks, | ↓ amylase, IL-1 | [ |
|
| ||||
| Male albino Wistar rats | p.o. 100 mg rutin/kg from 31st day till the experimental period | p.o. EtOH (8–12 g/kg/day) and HFD (22% fat) for 90 days | ↑ mRNA expressionof CARD | [ |
AngII: angiotensin II, AP: acute pancreatitis, AP-1: activator protein-1, AQP: aquaporin, CARD: caspase activation recruitment domain, d.f.: disease-free, DMSO: dimethyl sulfoxide, EAEEN: emodin-assisted early enteral nutrition, EEN: early enteral nutrition, ER: endoplasmic reticulum, f.c.i.v.i.: followed by continuous i.v. infusion of, fgl2: Fibrinogen-Like Protein 2, HPDM = N,N,N′-trimethyl-N′-(4-hydroxy-3-methylbenzyl)-1,3-propane diamine, gr.: groups, i.g.: intragastric, i.p.: intraperitoneal, i.v.: intravenous, i.v.b.: i.v. bolus, iNOS: inducible NO synthase, LPO: lipid peroxide, mCD14: membrane-bound cluster of differentiation 14 protein, MCP-1: monocyte chemoattractant protein-1, MDA: malondialdehyde, MIP-1α: Macrophage inflammatory protein-1α, MPO: myeloperoxidase, NAP78: neutrophil-activating peptide 78, NO: nitric oxide, NP: not provided, PDTC: pyrrolidine dithiocarbamate, pMΦs: peritoneal macrophages, PYD: pyrin domain of apoptosis-associated speck-like protein, r.i.BPD:retrograde injection into the bilio-pancreatic duct of, resp.: respectively, RPA: rat pancreatic acinar, s.c.: subcutaneous injection, SAP: severe AP, SD: Sprague-Dawley, SS: Sandostatin, TLR-4: Toll-like receptor 4, trt.: treatment, WA: Wistar-Albino.
Potential mechanisms of action of phytocompounds in pancreatitis.
|
| ||
|
| ||
| ↑ apoptosis | ↑ apoptosis (index) of pancreatic acinar cells | Artemisinin [ |
| ↑ Bax protein | Baicalin [ | |
| ↑ caspase-3 | Artemisinin [ | |
| Cytochrome C | Rhein [ | |
| ↑ p53 | Ligustrazine [ | |
| ↓ Bcl-2 protein renal | Baicalin [ | |
| ↓ p38 | Ligustrazine [ | |
| ↑ Bax protein | Baicalin [ | |
| ↑ Bax/Bcl-2 ratio | Rhein [ | |
| ↑ caspase-8, -9 | Crambene [ | |
| ↑ renal apoptotic indexes | Baicalin [ | |
| ↓ calcium overload in the cytoplasm | Emodin [ | |
| ↓ ER stress transducers | Emodin [ | |
| Modulates the posttranslational modifications of histone H3 | Nordihydroguaiaretic acid [ | |
|
| ||
| ↓ apoptosis | ↑ Bcl-2 | Resveratrol [ |
| ↑ mRNA expression of CARD | Rutin [ | |
| ↓ apoptosis of intestinal mucosa cells | Emodin [ | |
| ↓ Bax | Resveratrol [ | |
| ↓ caspase-1 | Rutin [ | |
| ↓ caspase-3, -8, -9, -12 | Grape seed proanthocyanidins [ | |
| ↓ caspases-3 expressions in brain | Resveratrol [ | |
| ↓ PYD | Rutin [ | |
|
| ||
|
| ||
|
| ||
| Inflammation markers | ↓ CRP | Emodin [ |
|
| ||
| Inflammation activators | ↓ AP-1 | Curcumin [ |
| ↓ ASC-NLRP3 | Rutin [ | |
| ↓ Erk | Ligustrazine [ | |
| ↓ I | Curcumin [ | |
| ↓ MCP-1 | Crambene [ | |
| ↓ MIP-1 | Artemisinin [ | |
| ↓ NAP78 | Curcumin [ | |
| ↓ NF- | Artemisinin [ | |
| ↓ phosphorylated p38 | Nordihydroguaiaretic acid [ | |
| ↓ PKC | Breviscapine [ | |
| ↓ TLR4 expression in pancreas | Curcumin [ | |
|
| ||
| Inflammation inhibitors | ↑ Nrf2 | Grape seed proanthocyanidins [ |
| ↑ PPAR | Curcumin [ | |
| ↑ IL-10 | Crambene [ | |
| ↑ ratio IL-10/ IFN- | Magnolol [ | |
|
| ||
| Promoting phagocytosis of apoptotic neutrophils | ↑ ICAM-3 and mCD14 expression in pMΦs | Emodin [ |
|
| ||
| Inflammation mediators | ↓ chemokine | Curcumin [ |
| ↓ cytokines | Rutin [ | |
| ↓ ET-1 | Baicalin [ | |
| ↓ ICAM-1 and VCAM-1 expression in the intestine | Resveratrol [ | |
| ↓ IFN- | Grape seed proanthocyanidins [ | |
| ↓ IL-18 | Rutin [ | |
| ↓ IL-1 | Artemisinin [ | |
| ↓ IL-6 | Baicalin [ | |
| ↓ IL-8 | Resveratrol [ | |
| ↓ PLA2 | Baicalin [ | |
| ↓ P-selectin | Baicalin [ | |
| ↓ TNF- | Baicalin [ | |
| ↓ WBC count | Curcumin [ | |
|
| ||
|
| ||
|
| ||
| Nitrosative enzymes | ↓ iNOS | Curcumin [ |
| ↓ iNOS in pMΦs | Resveratrol [ | |
|
| ||
| Nitrosation products | ↓ NO | Baicalin [ |
| ↓ 3-nitrotyrosine | Rutin [ | |
|
| ||
|
| ||
|
| ||
| Oxidative enzymes | ↓ MPO | Artemisinin [ |
| ↓ MPO hepatic | Emodin [ | |
|
| ||
| Protective antioxidant enyzmes/mechanisms | ↑ GPx | Rutin [ |
| ↑ catalase | Resveratrol [ | |
| ↑ HO-1 | Grape seed proanthocyanidins [ | |
| ↑ SOD | Emodin [ | |
| ↑ GSH | Nordihydroguaiaretic acid [ | |
|
| ||
| Oxidation products | ↓ HO | Curcumin [ |
| ↓ lipid hydroperoxides | Rutin [ | |
| ↓ LPO | ligustrazine [ | |
| ↓ MDA | Emodin [ | |
| ↓ oxidative stress index | Rutin [ | |
| ↓ protein carbonyls | Curcumin [ | |
| ↓ ROS generation | Hesperidin [ | |
| ↓ TBARS | Nordihydroguaiaretic acid [ | |
| ↓ pancreatic fgl-2 | Curcumin [ | |
| ↓ Pancreatic inflammation (pancreatic release of IL-1 | Artemisinin [ | |
|
| ||
| Protection against injury | ↑ heat shock proteins | Nordihydroguaiaretic acid [ |
|
| ||
| Blood flow | ↑ pancreatic blood flow | Emodin [ |
| ↑ 6-keto-PGF1 | Emodin [ | |
| ↑ PGE2 | Emodin [ | |
| ↓ AngII | Emodin [ | |
| ↓ TXB2 | Emodin [ | |
|
| ||
| Pancreatic fibrosis | Pancreatic fibrosis Ł ↑ TGF- | Crambene [ |
| Pancreatic fibrosis Ł ↓ collagen, fibronectin, laminin, pancreatic fibrosis | Emodin [ | |
|
| ||
|
| ||
|
| ||
| Lung inflammatory activators | ↓ NF- | Dihydroresveratrol [ |
| ↓ TLR4 expression | Emodin + baicalin/baicalein [ | |
| ↓ TNF- | Curcumin [ | |
| ↓ IL-1 | Dihydroresveratrol [ | |
| ↓ pulmonary | Dihydroresveratrol [ | |
| ↓ TNF- | Curcumin [ | |
|
| ||
| Lung nitrosative stress | ↓ iNOS lung | Curcumin [ |
|
| ||
| Lung function | ↓ lung hyperreactivity | Curcumin [ |
| ↑ claudin-4 | Emodin [ | |
| ↑ claudin-5 | Emodin [ | |
| ↑ occludin | Emodin [ | |
| ↑ AQP1 and AQP5 in lung | Emodin [ | |
|
| ||
|
| ||
|
| ||
| Bowel injury | ↓ bacteria and endotoxin translocation | Emodin [ |
| ↓ ICAM-1 and VCAM-1 expression in the intestine | Resveratrol [ | |